Cargando…
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
Autores principales: | Kizhakeyil, Atish, Zaini, Nurmahirah Binte Mohammed, Poh, Zhi Sheng, Wong, Brandon Han Siang, Loh, Xinpeng, Ng, Aik Seng, Low, Zun Siong, Prasannan, Praseetha, Gong, Chun, Tan, Michelle Guet Khim, Nagarajan, Chandramouli, Huang, Dachuan, Lu, Pang Wan, Lim, Jing Quan, Barrans, Sharon, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Follows, George, Hodson, Daniel J., Du, Ming Qing, Goh, Yeow Tee, Tan, Suat Hoon, Grigoropoulos, Nicholas Francis, Verma, Navin Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520256/ https://www.ncbi.nlm.nih.gov/pubmed/34654425 http://dx.doi.org/10.1186/s12943-021-01437-0 |
Ejemplares similares
-
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2021) -
No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2020) -
Centrosome- and Golgi-Localized Protein Kinase N-Associated Protein Serves As a Docking Platform for Protein Kinase A Signaling and Microtubule Nucleation in Migrating T-Cells
por: Ong, Seow Theng, et al.
Publicado: (2018) -
Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations
por: Chan, Jason Yongsheng, et al.
Publicado: (2023) -
Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)